Citations

Clear

225 citation(s) found for "Kenderian, Saad".

Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome
Kenderian, Saad S.

Mayo Clinic

JAMA Neurology | November 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.4155 | PMID 43002394 Get It

Importance Stiff person syndrome (SPS) is a progressive, autoimmune neurologic disease characterized by muscle stiffness and painful spasms, leading to substantial disability. Mivocabtagene autoleucel, a fully human, autologous CD19 chimeric antigen receptor (CAR) T-cell therapy with CD28 costimulation, showed durable clinical benefit on a named-patient basis in SPS. Objective To evaluate the efficacy and safety of mivocabtagene autoleucel in adult SPS. Design, Setting, and Participants This pivotal, single-arm, open-label, nonrandomized phase 2 study enrolled participants from September 2024 to May 2025 at 3 US sites. Individuals aged 18 to 75 years with antibody-positive SPS and inadequate response to immunomodulatory/immunosuppressive therapies as determined by investigators were included. Intervention Patients received low-dose lymphodepletion (fludarabine, 30 mg/m 2 /d, and cyclophosphamide, 300 mg/m 2 /d, for 3 days), followed by a single mivocabtagene autoleucel infusion (1 × 10 8 CAR T cells). Main Outcomes and Measures Primary end points were the change from baseline to week 16 in the timed 25-ft walk (T25FW) and safety. Secondary end points were modified Rankin Scale score, Distribution of Stiffness Index score, Heightened Sensitivity Scale score, and Hauser Ambulation Index score. Exploratory end points included pharmacokinetic and pharmacodynamic assessments and biomarkers. Results Of 27 patients enrolled, 26 (median [range] age, 56.0 [32.0-73.0] years; 16 [61.5%] female) were treated. Median (range) follow-up was 6.5 (4.4-12.2) months. The primary efficacy end point was met, with significant week 16 improvement from baseline in T25FW of a mean of −7.69 seconds (SD, 10.03; 95% CI, −11.74 to −3.64; P < .001) and a median (IQR) of −4.8 (−11.9 to −2.5) seconds (45.6% median improvement); improvement was sustained (median, 44.4%) among 16 of 26 patients who reached the 24-week time point. All secondary efficacy end points showed significant week 16 improvements from baseline (modified Rankin Scale score: mean, −0.8 points [SD, 0.86; 95% CI, −1.1 to −0.4; P < .001], Distribution of Stiffness Index score: mean, −1.5 points [SD, 1.75; 95% CI, −2.2 to −0.8; P < .001]; Heightened Sensitivity Scale score: mean, −3.2 points [SD, 2.01; 95% CI, −4.0 to −2.3; P < .001]; Hauser Ambulation Index score: mean, −1.6 points [SD, 1.13; 95% CI, −2.1 to −1.2; P < .001]). The most common grade 3/4 treatment-related adverse event was neutropenia (5/26 patients [19.2%]). Low-grade cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome occurred in 24 of 26 patients (92.3%; 10/26 [38.5%] grade 1; 14/26 [53.8%] grade 2) and 3 of 26 patients (11.5%; all grade 1), respectively; all resolved without sequelae. B-cell depletion and clear changes suggestive of immune reset were observed. At last follow-up, all patients remained free of immunomodulatory therapies for SPS. Conclusions and Relevance In this nonrandomized clinical trial, a single dose of mivocabtagene autoleucel resulted in immunotherapy-free remissions with a consistent, well-tolerated safety profile, demonstrating a highly effective therapy in antibody-positive SPS with the potential for durable remissions. Long-term follow-up is ongoing. Trial Registration ClinicalTrials.gov Identifier: NCT06588491
Two birds with one stone: faster, fitter CAR T cells
Kenderian, Saad S.

Mayo Clinic

Blood | August 6, 2026 | Volume: 148 | Issue: 6 | Pages: 644-646

10.1182/blood.2026034331 | PMID 42560719 Get It

TRAIL splice variant TRAILshort disrupts T cell receptor signaling and promotes immune tolerance in vivo
Jalali, Shahrzad , Natesampillai, Sekar, Nie, Zilin , Zhang, Ying, Chandrasekar, Aswath P. , Hameister, Brianna M., Correia, Cristina, Mun, Dong-Gi, Garcia-Rivera, Enrique, Matson, Robert , Krogman, Ashton, Maynes, Mark A., Batchelor, Robin, Monie, Dileep D. , Behfar, Atta, Ansell, Stephen M. , Taner, Timucin, Weyand, Cornelia, Billadeau, Daniel D. , Garcia-Rivera, Enrique , Zhao, Tuantuan V, Garcia-Rivera, Enrique , Monie, Dileep D , Can, İsmail , Correia, Cristina , Zhao, Tuantuan V. , Mun, Dong‐Gi , Krogman, Ashton , Maynes, Mark A , Li, Hu , Behfar, Atta , Kenderian, Saad S. , Pandey, Akhilesh , Taner, Timuçin , Weyand, Cornelia M. , Badley, Andrew D.

Mayo Clinic

Journal of Clinical Investigation | August 2, 2026 | Volume: 136 | Issue: 15 | Pages: No page available

10.1172/jci194449 | PMID 42544577 Get It

TRAIL is a TNF family ligand that trimerizes TRAIL-R1 (DR4) or TRAIL-R2 (DR5) to induce apoptosis, necroptosis, and/or NF-κB activation in receptor-bearing cells. We previously identified TRAILshort as a splice variant of TRAIL that lacks cysteine 230, cannot trimerize, and acts as a dominant-negative ligand that blocks TRAIL-mediated apoptosis. TRAILshort is expressed on cell surfaces and within extracellular vesicles, enabling it to confer TRAIL resistance to both producing and bystander cells. In this study, we showed that elevated TRAILshort levels were associated with chronic viral infections, cancer, and autoimmune diseases, suggesting a link to impaired immune regulation. Using unbiased phosphoproteomics and mechanistic studies, we demonstrated that TRAILshort binding to DR5 recruited and activated the phosphatase Src homology region 2 domain–containing phosphatase 1 (SHP-1), leading to zeta-chain-associated protein kinase 70 (ZAP-70) dephosphorylation, disruption of ZAP-70–CD3ζ interactions, and impaired T cell receptor signaling, thereby reducing T cell activation, proliferation, and cytokine production in response to antigen or CD3/CD28 ligation. Genetic or pharmacologic SHP-1 inhibition reverses these effects. In humanized mouse models, TRAILshort promoted the persistence of transformed mouse embryonic fibroblasts (MEFs) and L428 and antagonized CD19-directed CAR T cell activity, revealing TRAILshort as an immunomodulator of T cell function with therapeutic implications, including blocking TRAILshort to restore T cell immunity or delivering TRAILshort to enforce tolerance. TRAILshort, a variant of TRAIL, suppresses T cell function and immune responses in cancer and infectious diseases, highlighting its potential as a therapeutic target.
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda, William G. , Dorritie, Kathleen , Gauthier, Jordan , Nath, Rajneesh, Kipps, Thomas J. , Riedell, Peter A. , Eradat, Herbert A., Kharfan‐Dabaja, Mohamed A. , Shah, Nirav N. , Solomon, Scott R., Stephens, Deborah M., Ermann, Daniel A., Arnason, Jon , Deol, Abhinav , Feldman, Tatyana , Ghosh, Monalisa , Tuazon, Sherilyn A., Perna, Serena K., Ou, San-San, Ananthakrishnan, Revathi , Rane, Neha, Papp, Eniko, Ansari, Sahar , Thompson, Ethan G., Okal, Abood, Peiser, Leanne, Chen, Yizhe , Sengupta, Sanhita , Wang, Jixian , Wierda, William G. , Dorritie, Kathleen , Kenderian, Saad S. , Kharfan-Dabaja, Mohamed A , Shah, Nirav N , Deol, Abhinav , Ma, Shuo , Schuster, Stephen J , Gergis, Usama , Vose, Julie , Soumerai, Jacob D , Besien, Koen van , Chen, Yizhe , Sengupta, Sanhita , Ray, Pradipta Ranjan , Siddiqi, Tanya , Kipps, Thomas J , Riedell, Peter A , Nath, Rajneesh , Eradat, Herbert, Stephens, Deborah M. , Andreadis, Charalambos Babis , Ma, Shuo , Schuster, Stephen J. , Vose, Julie M. , Soumerai, Jacob D. , Tuazon, Sherilyn A. , Perna, Serena , Ou, San‐San , Papp, Eniko , Ansari, Sahar, Siddiqi, Tanya

Mayo Clinic

Blood Journal | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033565 | PMID 42520199 Get It

Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
Siglec-9 is a functional inhibitory receptor for B7-H3 that regulates anti-tumor immunity 2260091
Medlyn, Michael, Shapiro, Michael, Kimball, Brooke, Huynh, Truc, Peterson, Kevin, Crotts, Sydney, Zastrow, Alexi, Lucien, Fabrice, Kaufmann, Scott, Kenderian, Saad, Billadeau, Daniel, Shapiro, Virginia, Chen, Yin, Medlyn, Michael J. , Shapiro, Michael, Kimball, Brooke , Huynh, Truc , Crotts, Sydney B. , Zastrow, Alexi, Lucien, Fabrice , Kenderian, Saad, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.853 Get It

Abstract Introduction Checkpoint blockade revolutionized cancer therapy. However, only a small proportion of cancers respond to checkpoint blockade. B7-H3 is a member of the B7 superfamily, which includes both co-inhibitory and co-stimulatory receptors. B7-H3 is upregulated by many tumors which is generally associated with a worse prognosis. However, the exact mechanism by which B7-H3 suppresses the immune response remains elusive. Methods We transfected human HEK293T cells and assessed the binding to recombinant Siglecs via flow cytometry. We generated monoclonal antibody F7 against human B7-H3 and tested its blocking function using B7-H3 transfected HEK293T cells. We examined the extent of degranulation and NK cell-mediated killing on B7-H3 expressing HEK293T cells in vitro, as well as the CART19 cells mediated killing in relapse model of B7-H3 expressing CD19+ leukemia Nalm6 cells NSG mice. Results We demonstrated that sialylated B7-H3 binds to the inhibitory receptor Siglec-9 on immune cells but not to the related protein Siglec-7. A high affinity monoclonal antibody (mAb) F7 against B7-H3 blocks Siglec-9 binding. Functionally, F7 enhances NK cell killing of B7-H3 expressing target cells in vitro. F7 also dramatically enhances CART19 mediated killing of B7-H3 expressing Nalm6 cells in a relapse model in NSG mice in vivo. Conclusion We have now shown for the first time that B7-H3 binds to the inhibitory receptor Siglec-9 and generated a novel monoclonal antibody F7 that target a unique sequence in B7-H3 as compared to other monoclonal antibodies being examined for clinical efficacy. F7 can promote NK cell killing of B7-H3 expressing target cells in vitro and synergize with CART19 to enhance killing of B7-H3 expressing tumor cells in vivo. As B7-H3 is overexpressed in many human cancers, this work is critical toward understanding how B7-H3 mediates immune evasion through Siglec-9 for enhancing anti-tumor immunity. Funding Source R01CA243545-01A1 Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Risk‐Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients
Alsugair, Ali, Fathima, Saubia , Alhousani, Mohammad , Mariotti, E, Bolarinwa, Abiola , Faldu, Priyansh, Yousuf, Muhammad , Foran, James M. , Mangaonkar, Abhishek A. , Litzow, Mark, Sproat, Lisa, Palmer, Jeanne , Matin, Aasiya , Ayala, Ernesto , Slack, James L., Porrata, Luis, Khera, Nandita , Punwani, Nathan , Begna, Kebede H. , Pardanani, Animesh , Gangat, Naseema , Patnaik, Mrinal M. , Tefferi, Ayalew , Gauto‐Mariotti, Estefania , Alsugair, Ali , Alhousani, Mohammad M , Mariotti, Estefania Gauto , Csizmar, Clifford M. , Foran, James M , Mangaonkar, Abhishek A. , Litzow, Mark R. , Murthy, Hemant S , Matin, Aasiya , Ayala, Ernesto , Slack, James, Porrata, Luis , Iqbal, Madiha , Khera, Nandita , Kenderian, Saad Sirop , Chhabra, Saurabh , Pardanani, Animesh , Hogan, William J , Shah, Mithun V , Alkhateeb, Hassan B , Gangat, Naseema , Patnaik, Mrinal , Tefferi, Ayalew , Fathima, Saubia , Bolarinwa, Abiola B , Faldu, Priyansh, Murthy, Hemant S. , Iqbal, Madiha , Kenderian, Saad S. , Chhabra, Saurabh , Hogan, William J. , Shah, Meera , Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Hematology | July 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70453 | PMID 42499183 Get It

ABSTRACT The recently published BLAST clinical risk model for chronic myelomonocytic leukemia (CMML) and its molecular version (BLAST‐Mol) differentiate low, intermediate, and high‐risk groups. The objective of the current retrospective study was to examine the survival impact of allogeneic stem cell transplant (ASCT) in a consecutive series of Mayo Clinic patients ( n = 775; 68% males, median age 71 years) with CMML, overall and adjusted for baseline BLAST/BLAST‐Mol risk categories. At a median follow‐up of 77 months, 151 (20%) patients underwent ASCT. Overall survival (OS) was longer in the ASCT compared to the non‐ASCT cohorts (median 77 vs. 28 months; p < 0.01). The significant difference in OS between the ASCT and non‐ASCT cohorts was retained after adjusting for BLAST clinical risk groups: high‐risk (median 50 vs. 14 months; p < 0.01), intermediate‐risk (81 vs. 28 months; p < 0.01), and low‐risk (111 vs. 65 months; p = 0.04), respectively. The same was mostly the case when OS comparison was adjusted for BLAST‐Mol with respective p values of < 0.01, < 0.01, and 0.08, respectively. Time‐dependent cox models confirmed the favorable survival impact of ASCT in the BLAST/BLAST‐Mol high‐ and intermediate‐risk groups. The current study highlights the benefit of ASCT for BLAST/BLAST‐Mol high‐ and intermediate‐risk groups in CMML and its potential to overcome the adverse impact of some high risk cytogenetic or molecular abnormalities. These observations support the early use of ASCT in CMML, ideally before BT and regardless of genetic characteristics.
Sleeping Beauty mutagenesis identifies BACH2 and other regulators of CD8 + T-cell exhaustion, persistence in vivo, and CAR-T cell f
Lee, Chungchi , Larsson, Alex T, Jubenville, Tyler A, Hudson, Wendy A, Seeman, Zach J, Stewart, Carli M. , Tsai, Alexander K. , Burrack, Adam, Kimball, Brooke L, Siegler, Elizabeth L, Vianzon, Vianca , Nolan, Erin E, Yang, Yu-Ling, Stehn, Christopher M, Gohl, Daryl M, Donovan, Margaret, Temiz, Nuri A, Popescu, Flavia E, Warming, Søren, Seshagiri, Somasekar, You, Yun, Riordan, Jesse D, Dupuy, Adam, Moriarity, Branden, Stromnes, Ingunn M. , Kenderian, Saad, Largaespada, David A. , Gohl, Daryl M. , Lee, Chang-Jung , Stewart, Carli , Vianzon, Vianca V , Rogers, Laura M , Stromnes, Ingunn M , Largaespada, David A. , Tsai, Alexander K , Larsson, Alex T. , Jubenville, Tyler , Hudson, Wendy A. , Seeman, Zachary J. , Burrack, Adam L. , Kimball, Brooke , Siegler, Elizabeth L. , Nolan, Erin E. , Stehn, Christopher M. , Donovan, Margaret , Temiz, Nuri A. , Popescu, Flavia E., Seshagiri, Somasekar , Riordan, Jesse D. , Dupuy, Adam J. , Moriarity, Branden S. , Rogers, Laura M. , Kenderian, Saad

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 15, 2026 | Volume: 14 | Issue: 7 | Pages: e013536

10.1136/jitc-2025-013536 | PMID 42457339 Get It

Background Genes that enhance T-cell function represent promising targets for improving engineered T-cell therapies for cancer. While extensive CRISPR knockout screens have identified key genes enhancing T-cell persistence, employing Sleeping Beauty ( SB ) insertional mutagenesis, which induces both gain-of-function (GOF) and loss-of-function (LOF) mutations via the generation of fusion transcripts with endogenous genes, may uncover additional critical factors that previous approaches have overlooked. Methods We developed transgenic mice carrying D oxycycline (Dox)- i nducible SB mutag e nesis s y stem (DiSBey) in primary T cells. Using DiSBey, we conducted screens for genetic alterations enhancing T-cell persistence under chronic antigen exposure. Specifically, CD8 + T cells from Dox-fed DiSBey mice were subjected to repeated anti-CD3 stimulation over 18 days to mimic chronic antigenic stimulation. We then identified SB transposon genomic insertion sites and corresponding fusion transcripts from the persistent DiSBey CD8 + T cells using enhanced-specificity tagmentation sequencing and RNA sequencing, respectively. Results Under chronic stimulation, SB -mutagenized CD8 + T cells exhibited improved persistence and reduced terminal exhaustion phenotype. Across six independent screens, we identified 38 genes that were recurrently targeted by the SB transposon T2/Onc2 and differentially expressed under chronic anti-CD3 stimulation. T2/Onc2 insertions into Bach2 and Elmo1 were recurrently identified at the genomic level and were associated with altered nascent transcript expression. Bach2 , known as a key regulator of T-cell memory formation and resistance to chronic viral infection-induced exhaustion but less characterized in engineered T cells for cancer therapy, was found to counteract exhaustion in vitro and enhance in vivo tumor persistence in the B16-Ova tumor model. Further, we showed that ectopic Bach2 expression levels influence engineered T-cell differentiation lineage, as low Bach2 overexpression retained more functional progenitor exhausted T cells and exhibited improved therapeutic efficacy. Finally, in human CART19-28ζ cells, BACH2 overexpression enhanced cytotoxicity and tumor control following chronic cancer stimulation. Conclusions Controllable SB mutagenesis using DiSBey mice provides a novel platform for functional screening of genes that improve T-cell phenotypes important for their use as therapies. Our findings highlight a dose-dependent role of BACH2 in enhancing the function of engineered T cells under conditions of chronic antigenic stimulation.
Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)
Ζεκερίδου, Αναστασία , Gutman, Jonathan, Lowe, Mallory, Eggmann, Sadie, McKeon, Andrew, Pittock, Sean J., Yi, Jessica J., Newsome, Scott D., Chou, Justin, Blarcom, Tom Van, Han, Xue, Sun, John, Sengupta, Shouvonik , Tooker, Ryan, Mehta, Aditi, Grayson, Dena , Gehchan, N., Piquet, Amanda L. , Gergis, Usama , Gutman, Jonathan A. , Kenderian, Saad S. , McKeon, Andrew , Pittock, Sean J. , Rakočević, Goran , Dalakas, Marinos C.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217905 Get It

Abstract 1525: Optimized CART cell therapy to remodel the tumor microenvironment and eliminate GI malignancies
Ruiz, Omar L Gutierrez, Sakemura, R. Leo, Skeele, Dominic, Saleh, Ateka, Can, Ismail, Sirpilla, Olivia , Yun, Kun , Stewart, Carli M. , Hefazi, M., Yamaguchi, Yoh, Fonkoua, Lionel Aurelien Kankeu, K, Long, Huynh, Truc, Goldberg, Sophia Y., DeFranco, Grace , Foote, Sara G., Ogbodo, Ekene Johnkennedy Newton, Xia, Hong , Redig, Michael, Matthew, Matthew L., Turley, Tamiel Nichole, Klinge, Skyeler, Copland, John Alton, Kenderian, Saad J., Gutierrez-Ruiz, Omar L. , Ruiz, Omar Gutierrez, Feigin, Jennifer M. , Kimball, Brooke , Sakemura, Reona , Siegler, Elizabeth L. , Roman, Claudia Manriquez , Can, İsmail , Stewart, Carli , Hefazi, Mehrdad , Yamaguchi, Yoh, Fonkoua, Lionel Aurelien Kankeu , Huynh, Truc , Goldberg, Sophia , Ogbodo, Ekene J. , Turley, Tamiel N. , Copland, John A.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1525-1525

10.1158/1538-7445.am2026-1525 Get It

Abstract Gastrointestinal (GI) cancers are rising in people &lt; 50 and remain major causes of cancer mortality despite therapeutic advances. Chimeric antigen receptor T (CART) cell therapy has transformed treatment of hematological cancers. However, its efficacy in GI cancers has been hindered by antigen heterogeneity and immunosuppressive cancer associated fibroblasts (CAFs) in the tumor microenvironment (TME.) Here we aimed to 1) study CART-CAF interactions and 2) engineer CART cells capable of eliminating CAFs to overcome their inhibitory role and enhance their antitumor activity in GI cancers. We first analyzed primary CAFs from 20 GI cancer patients. CAFs showed high fibroblast activation protein (FAP) expression and significantly suppressed T cells proliferation (26-77%, p≤0.0001). We next generated CART cells capable of safely eliminating both GI cancer cells and CAFs. To target cancer cells, we developed a novel nanobody (VHH)-based CAR against Claudin18.2, a GI cancer specific target. To avoid off-tumor toxicity in healthy FAP+ tissues, we incorporated an inducible FAP-CAR using the synNotch platform, enabling conditional targeting upon engagement with Claudin18.2+ cells, restricting FAP targeting within the TME. VHH Claudin18.2 CART cells showed superior specificity and efficacy vs scFv-based CART cells (hu8E85 or zolbetuximab). In Claudin18.2+ SNU-C2B xenografts, tumors were 92mm3 (VHH) vs 48mm3 (huE85) vs 211mm3 (zolbetuximab) on day 23 post-CART, median survival undefined vs 17 days vs 23 days respectively; p=0005. In Claudin18.2+ LS411N xenografts, tumors were 315mm3 vs 106mm3 vs 382 mm3 respectively at 23 days post-CART, median survival undefined vs 19 days vs undefined respectively; p=0004. VHH Claudin18.2 CART cells showed no off-tumor effects, while hu8E85 CART induced significant toxicity. We next established a co-engraftment model. NSG mice received 1x106 SNU-C2B and 6x106 CAFs from a GI cancer patient. At 500 mm3 tumors, mice received 5x106 VHH Claudin18.2 or inducible Claudin18.2/FAP CART. Dual-targeting CART cells showed greater antitumor response (728mm3 vs 320mm3, p=0.0011 at day 20 post-CART), expansion (61 vs 2,350 CART/µl of blood, p=0.0037), and tumor infiltration (8.71 x 105 vs 1.03 x 106 CART/g of tumor, p&lt;0.0001). This was also observed in gastric, colon, and pancreatic PDX models, with no observable off-tumor cytotoxic effects with inducible dual-targeting Claudin18.2/FAP CART. Our findings demonstrate that our novel VHH-based Claudin18.2 CART cells are highly specific and effective against GI malignancies, and that inducible Claudin18.2/FAP dual-targeting CART cells safely remodel the TME into an immune-permissive state. This approach represents a mechanistically innovative and translationally relevant strategy to overcome CAF-mediated immunosuppression, enhance CART cell efficacy, and improve clinical outcomes in refractory solid tumors. Citation Format: Omar L. Gutierrez Ruiz, Jennifer Feigin, Brooke Kimball, R. Leo Sakemura, Elizabeth L. Siegler, Dominic A. Skeele, Ateka Saleh, Claudia Manriquez Roman, Ismail Can, Olivia Sirpilla, Kun Yun, Carli M. Stewart, Mehrdad Hefazi, Yoh Yamaguchi, Lionel Aurelien Kankeu Fonkoua, Long K. Mai, Truc Huynh, Sophia Y. Goldberg, Grace E. DeFranco, Sara Foote, Ekene Johnkennedy Newton Ogbodo, Hong Xia, Michael Redig, Matthew L. Matthew, Tamiel Nichole Turley, Skyeler Klinge, John Alton Copland, Saad J. Kenderian. Optimized CART cell therapy to remodel the tumor microenvironment and eliminate GI malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1525.